A new probabilistic rule for drug-dug interaction prediction

Journal of Pharmacokinetics and Pharmacodynamics

Volumn 36, Issue 1, 2009, Pages 1-18

  Zhou, Jihao ^a   Qin, Zhaohui ^a   Quinney, Sara K ^b   Kim, Seongho ^b   Wang, Zhiping ^b   Yu, Menggang ^b   Chien, Jenny Y ^c   Lucksiri, Aroonrut ^b   Hall, Stephen D ^b   Li, Lang ^a,d  

^a UNIVERSITY OF MICHIGAN   (United States)

^b INDIANA UNIVERSITY   (United States)

^c ELI LILLY AND COMPANY   (United States)

^d NONE   (United States)

Author keywords

Area under the concentration curve ratio (AUCR); Bayesian model; Drug drug interaction (DDI); Pharmacokinetics; Prediction

Indexed keywords

KETOCONAZOLE; MIDAZOLAM;

AREA UNDER THE CURVE; ARTICLE; DRUG EFFECT; DRUG FORMULATION; DRUG INHIBITION; HUMAN; IN VIVO STUDY; PRIORITY JOURNAL;

ALGORITHMS; AREA UNDER CURVE; BAYES THEOREM; COMPUTER SIMULATION; CYTOCHROME P-450 CYP3A; DRUG INTERACTIONS; FASTING; FEMALE; HUMANS; KETOCONAZOLE; MALE; META-ANALYSIS AS TOPIC; MIDAZOLAM; MODELS, STATISTICAL; MONTE CARLO METHOD; PHARMACOKINETICS; PROBABILITY;

EID: 58249137368     PISSN: 1567567X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10928-008-9107-3     Document Type: Article

References (29)

1. BP Monahan CL Ferguson ES Killeavy BK Lloyd J Troy LR Cantilena Jr 1990 Torsades de pointes occurring in association with terfenadine use JAMA 264 21 2788 2790
2. T Watabe 1996 Strategic proposals for predicting drug-drug interactions during new drug development: based on sixteen deaths caused by interactions of the new antiviral sorivudine with 5-fluorouracil prodrugs J Toxicol Sci 21 5 299 300
3. H Okuda T Nishiyama K Ogura S Nagayama K Ikeda S Yamaguchi Y Nakamura Y Kawaguchi T Watabe 1997 Lethal drug interactions of sorivudine, a new antiviral drug, with oral 5-fluorouracil prodrugs Drug Metab Dispos 25 5 270 273
4. K Ito T Iwatsubo S Kanamitsu K Ueda H Suzuki Y Sugiyama 1998 Prediction of pharmacokinetic alterations caused by drug-drug interactions: metabolic interaction in the liver Pharmacol Rev 50 3 387 412
5. K Ito T Iwatsubo T Kanamitsu S Nakajima Y Sugiyama 1998 Quantitative prediction of in vivo drug clearance and drug interactions from in vitro data on metabolism, together with binding and transport Annu Rev Pharmacol Toxicol 38 461 499
6. J Yang M Kjellsson A Rostami-Hodjegan GT Tucker 2003 The effects of dose staggering on metabolic drug-drug interactions Eur J Pharm Sci 20 2 223 232
7. K Ito K Chiba M Horikawa M Ishigami N Mizuno J Aoki Y Gotoh T Iwatsubo S Kanamitsu M Kato I Kawahara K Niinuma A Nishino N Sato Y Tsukamoto K Ueda T Itoh Y Sugiyama 2002 Which concentration of the inhibitor should be used to predict in vivo drug interactions from in vitro data? AAPS Pharmsci 4 4 E25
8. L Li M Yu R Chin A Lucksiri D Flockhart DS Hall 2007 Drug-drug Interaction prediction: a Bayesian meta-analysis approach Stat Med 26 20 3700 3721
9. Yu M, Kim S, Wang, Z, Hall DS, Li L (2007) A Bayesian meta-analysis on published sample mean and variance pharmacokinetic data with application to drug-drug interaction prediction. J Biopharm Stat (in press)
10. SM Tsunoda RL Velez LL von Moltke DJ Greenblatt 1999 Differentiation of intestinal and hepatic cytochrome P450 3A activity with use of midazolam as an in vivo probe: effect of ketoconazole Clin Pharmacol Ther 66 5 461 471
11. JD Cleary JW Taylor SW Chapman 1992 Itraconazole in antifungal therapy Ann Pharmacother 26 4 502 509
12. PS Price RB Conolly CF Chaisson EA Gross JS Young ET Mathis DR Tedder 2003 Modeling interindividual variation in physiological factors used in PBPK models of humans Crit Rev Toxicol 33 5 469 503
13. R Martinez-Jorda JM Rodriguez-Sasianin R Calvo 1990 Serum binding of ketoconazole in health and disease Int J Clin Pharmacol Res 5 271 276
14. Rowland M, Tozer TN (1995) Clinical pharmacokinetics concept and applications, 3rd edn. Lippincott Williams & Wilkins, London
15. L Van A Heydari J Yang J Hargreaves K Rowland-Yeo MS Lennard GT Tucker A Rostami-Hodjegan 2006 The impact of experimental design on assessing mechanism-based inactivation of CYP2D6 by MDMA (Ecstasy) J Psychopharmacol 20 834 841
16. JC Wakefield AFM Smith A Racine-Poon AE Gelfand 1994 Bayesian analysis of linear and non-linear population models by using the Gibbs sampler Appl Stat 43 201 221
17. JC Wakefield 1996 Bayesian individualization via sampling-based methods J Pharmacokinet Biopharm 24 1 103 131
18. JC Wakefield 1996 The Bayesian analysis of population pharmacokinetic models J Am Stat Assoc 91 62 75
19. JC Wakefield JE Bennett 1996 The Bayesian modeling of covariates for population pharmacokinetic models J Am Stat Assoc 91 917 927
20. JC Wakefield N Rahman 2000 The combination of population pharmacokinetic studies Biometrics 56 1 263 270
21. HF Lopes P Muller GL Rosner 2003 Bayesian meta-analysis for longitudinal data models using multivariate mixture priors Biometrics 59 1 66 75
22. A Rostami-Hodjegan G Tucker 2004 "In Silico" simulations to assess the "in vivo" consequences of "in vitro" metabolic drug-drug interactions Drug Discov Today Technol 1 441 448
23. A Gelman DB Rubin 1992 Inference from iterative simulation using multiple sequences Stat Sci 7 457 472
24. EW Gascoigne GJ Barton M Michaels W Meuldermans J Heykans 1991 The kinetics of ketoconazole in animals and man Clin Res Rev 1 3 177 187
25. TK Daneshmend DW Warnock A Turner CJ Roberts 1981 Pharmacokinetics of ketoconazole in normal subjects J Antimicrob Chemother 8 299 304
26. TK Daneshmend DW Warnock MD Ene EM Johnson G Parker MD Richardson CJ Roberts 1983 Multiple dose pharmacokinetics of ketoconazole and their effects on antipyrine kinetics in man J Antimicrob Chemother 12 2 185 188
27. TK Daneshmend DW Warnock MD Ene EM Johnson MR Potten MD Richardson PJ Williamson 1984 Influence of food on the pharmacokinetics of ketoconazole Antimicrob Agents Chemother 25 1 1 3
28. YC Huang JL Colaizzi RH Bierman R Woestenborghs J Heykants 1986 Pharmacokinetics and dose proportionality of ketoconazole in normal volunteers Antimicrob Agents Chemother 30 2 206 210
29. JI Lee D Chaves-Gnecco JA Amico PD Kroboth JW Wilson RF Frye 2002 Application of semisimultaneous midazolam administration for hepatic and intestinal cytochrome P450 3A phenotyping Clin Pharmacol Ther 72 6 718 728